Myriad Genetics, Inc. (MYGN)
NGS · Common · CUSIP 62855J104
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for MYGN and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
62855J104
Market Cap
Large Cap
Business: Myriad Genetics, Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

Company Contact

CEO
Samraat S. Raha
CFO
Benjamin R. Wheeler
Headquarters
322 North 2200 West, Salt Lake City, UT 84116
Phone
801-584-3600
Fax
801-584-3640
Investor Relations
Scott Gleason · 801-584-1143 · sgleason@myriad.com
Email Form
Contact Form »
SEC EDGAR Filings
View filings »